Diversified Consumer Services
Company Overview of University of Liverpool
University of Liverpool is an educational institution that offers undergraduate, post graduate, and online programmes in the fields of science, law, philosophy, psychology, music, architecture, and media. The institution is based in Liverpool, United Kingdom.
Liverpool, L69 3BX
Key Executives for University of Liverpool
Director of Business Services
Compensation as of Fiscal Year 2017.
University of Liverpool Key Developments
Proton Partners International Signs Research Agreement with the University of Liverpool
Apr 19 17
Proton Partners International has signed a research agreement with the University of Liverpool. The company has agreed a two-year collaborative research project with the university to enhance proton beam therapy technology. The project will develop a new measurement system, known as a 3D Water Phantom, which it is hoped will further improve the accuracy of proton beam therapy treatment. The new system will use pixelated silicon detectors, first developed at CERN, the European Organisation for Nuclear Research. Improved accuracy will lead to better modelling and calibration of treatment beams, which will offer more advanced treatment for patients. It will also allow for more accurate clinical research and development to be undertaken.
The Medicines Patent Pool Inks Agreement with the University of Liverpool to Develop HIV Nanomedicines
Dec 3 15
The Medicines Patent Pool reported a collaboration with the University of Liverpool and a license for the university's Solid Drug Nanoparticle technology to accelerate the development of WHO-recommended antiretrovirals as nanomedicines. The agreement covers a territory of all 135 low- and middle-income countries and two high-income countries in Africa, where licensees based anywhere in the world will have the right to make, use and distribute lower cost ARVs based on SDN technology. Under the terms of the agreement, the University of Liverpool will develop nanoparticles of ARVs licensed to the MPP such as atazanavir, darunavir and lopinavir to improve their solubility and thus reduce dosage. The MPP and the University of Liverpool will engage with pharmaceutical partners for product development and industrial scale-up. The MPP will then sub-license the nano-formulated ARVs and facilitate competitive manufacturing to spur wide distribution of the new medicines in low- and middle-income countries.
Eisai to Commence Two Joint Research Programs Toward Development of New Antimalarial Medicines
Nov 5 15
Eisai Co., Ltd. entered into two joint research agreements for the development of new antimalarial medicines. The first of these agreements is a joint development program with the Liverpool School of Tropical Medicine and the University of Liverpool. Under this agreement, the three parties will conduct preclinical development of a new antimalarial candidate compound E209. Research so far has shown that E209 is rapidly acting and shows efficacy against all types of malaria parasites, which means that it could be effective in patients for whom artemisinin-based malaria treatments are ineffective due to resistance. The second agreement is a joint development program with the non-profit public-private product development partnership Medicines for Malaria Venture (Location: Geneva, Switzerland, "MMV"). Under this agreement, Eisai and MMV aim to ultimately identify antimalarial candidate compounds with novel mechanisms of action that will be effective against malaria parasites resistant to existing treatments, as well as prevent relapse and block transmission to mosquitoes. This involves the optimization of compounds developed by Eisai that inhibit the biosynthesis of glycosylphosphatidylinositol (GPI) necessary for the growth of malaria parasites, and of a hit series of compounds identified from Eisai's compound library through joint research with MMV.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|